Skip to main content
  • Register
  • Help
  • Contact us
  • Log out of your HL account

Cleveland BioLabs Inc (CBLI) USD0.005

Sell:$0.70 Buy:$1.93 Change: $0.0599 (8.44%)
NASDAQ:0.20%
Market closed |  Prices as at close on 13 December 2019 | Switch to live prices |
Sell:$0.70
Buy:$1.93
Change: $0.0599 (8.44%)
Market closed |  Prices as at close on 13 December 2019 | Switch to live prices |
Sell:$0.70
Buy:$1.93
Change: $0.0599 (8.44%)
Market closed |  Prices as at close on 13 December 2019 | Switch to live prices |
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

Cleveland BioLabs, Inc. (CBLI) is a biopharmaceutical company. The Company is engaged in developing approaches to activate the immune system and address serious medical needs. Its platform of Toll-like immune receptor activators has applications in mitigation of radiation injury and immuno-oncology. Its advanced product candidate is Entolimod, an immuno-stimulatory agent, which it is developing as a radiation countermeasure and an immunotherapy for oncology and other indications. Its other products include CBLB612, Mobilan and CBL0137. CBLB612 is a compound based upon a natural activator of another tissue-specific component of the innate immune system, the toll-like receptor 2 (TLR2)/ toll-like receptor 6 (TLR6) heterodimeric receptor. Mobilan is a recombinant non-replicating adenovirus that directs expression of TLR5 and its agonistic ligand. CBL0137 is a small molecule with a multi-targeted mechanism of action that may be useful for the treatment of various types of cancer.

Contact details

Address:
73 High St
BUFFALO
14203-1149
United States
Telephone:
+1 (716) 8496810
Website:
www.cbiolabs.com/

Important dates

Future events
There are no future events available.
Past events
There are no past events available.

General stock information

Short code:
CBLI
ISIN:
US1858602022
Market cap:
$7.97 million
Shares in issue:
11.30 million
Sector:
Biotechnology
Exchange:
NASDAQ
Country:
United States
Currency:
US dollar
Indices:
NASDAQ Comb. Composite

Key personnel

  • Langdon Miller
    President
  • Yakov Kogan
    Chief Executive Officer, Chief Financial Officer, Secretary
  • Andrei Gudkov
    Chief Scientific Officer

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by Reuters.

Share

The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.